-
Product Insights
NewCoronary Artery Disease (CAD) (Ischemic Heart Disease) – Drugs In Development, 2024
Empower your strategies with our Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Drugs In Development, 2024 report and make more profitable business decisions. Coronary artery disease (CAD) is the most common type of heart disease. CAD happens when the arteries that supply blood to heart muscle become hardened and narrowed. This is due to the buildup of cholesterol and other material, called plaque, on their inner walls. This buildup is called atherosclerosis. As it grows, less blood can flow through...
-
Product Insights
NewMyocardial Infarction – Drugs In Development, 2024
Empower your strategies with our Myocardial Infarction – Drugs In Development, 2024 report and make more profitable business decisions. Myocardial infarction is the irreversible necrosis of heart muscle secondary to prolonged ischemia. Symptoms include pain, fullness, and/or squeezing sensation of the chest; jaw pain, toothache, or headache; shortness of breath; nausea, vomiting, and/or general epigastric discomfort; sweating, heartburn and/or indigestion; arm pain; upper back pain; and general malaise (vague feeling of illness). The Myocardial Infarction drugs in development market research report...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MiSaver in Myocardial Infarction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MiSaver in Myocardial Infarction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.MiSaver in Myocardial InfarctionDrug Details:MiSaver is under development for the treatment after a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CVN-766 in Schizophrenia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. CVN-766 in Schizophrenia Drug Details: CVN-766 is under development for the treatment of anxiety disorders,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – MiSaver
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry MiSaver Drug Details MiSaver is under development for the treatment after a heart attack...
-
Product Insights
Myocardial Infarction Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Myocardial infarction pipeline market research report provides a comprehensive overview on the therapeutics under development for Myocardial infarction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial infarction and features...